Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancer

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Wang, Jinhua ^a,b,c   Sharma, Ashok ^a   Ghamande, Sharad A ^a   Bush, Stephen ^a   Ferris, Daron ^a   Zhi, Wenbo ^a   He, Mingfang ^a,b   Wang, Meiyao ^a   Wang, Xiaoxiao ^a   Miller, Eric ^a   Hopkins, Diane ^a   Macfee, Michael ^a   Guan, Ruili ^a,d   Tang, Jinhai ^b,c   She, Jin Xiong ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b NANJING TECH UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CA 125 ANTIGEN; FAS ANTIGEN; GLYCOPROTEIN GP 130; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6 RECEPTOR; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; RANTES; SERUM AMYLOID A; SOMATOMEDIN; TUMOR MARKER; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; VERY ELDERLY;

BLOOD PROTEINS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84892941529     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078393     Document Type: Article

References (51)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
3. Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer. Lancet 374: 1371-1382.
4. Langmar Z, Nemeth M, Vlesko G, Kiraly M, Hornyak L, et al. (2011) HE4 - a novel promising serum marker in the diagnosis of ovarian carcinoma. Eur J Gynaecol Oncol 32: 605-610.
5. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, et al. (2010) Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 28: 2159-2166.
6. Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, et al. (2011) Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol 122: 548-553.
7. Autelitano DJ, Raineri L, Knight K, Bannister K, Rice GE (2012) Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women. J Transl Med 10: 45.
8. Edgell T, Martin-Roussety G, Barker G, Autelitano DJ, Allen D, et al. (2010) Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol 136: 1079-1088.
9. Hefler-Frischmuth K, Hefler LA, Heinze G, Paseka V, Grimm C, et al. (2009) Serum C-reactive protein in the differential diagnosis of ovarian masses. Eur J Obstet Gynecol Reprod Biol 147: 65-68.
10. Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, et al. (2005) Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 14: 981-987.
11. Antovska SV, Bashevska N, Aleksioska N (2011) Predictive values of the ultrasound parameters, CA-125 and risk of malignancy index in patients with ovarian cancer. Klin Onkol 24: 435-442.
12. Das PM, Bast RC, Jr. (2008) Early detection of ovarian cancer. Biomark Med 2: 291-303.
13. Jelovac D, Armstrong DK (2011) Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 61: 183-203.
14. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140: 883-899.
15. Wu Y, Zhou BP (2009) Inflammation: a driving force speeds cancer metastasis. Cell Cycle 8: 3267-3273.
16. Disis ML (2010) Immune regulation of cancer. J Clin Oncol 28: 4531-4538.
17. Rustin GJ, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, et al. (2006) Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol 24: 45-51.
18. Edgell T, Martin-Roussety G, Barker G, Autelitano DJ, Allen D, et al. (2010) Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol 136: 1079-1088.
19. Kim K, Visintin I, Alvero AB, Mor G (2009) Development and validation of a protein-based signature for the detection of ovarian cancer. Clin Lab Med 29: 47-55.
20. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, et al. (2008) Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14: 1065-1072.
21. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, et al. (2005) Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 102: 7677-7682.
22. Yip P, Chen TH, Seshaiah P, Stephen LL, Michael-Ballard KL, et al. (2011) Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers. PLoS One 6: e29533.
23. Hogdall C, Fung ET, Christensen IJ, Nedergaard L, Engelholm SA, et al. (2011) A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer. Gynecol Oncol 123: 308-313.
24. Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, et al. (2011) Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol 122: 548-553.
25. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, et al. (2011) A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) 4: 375-383.
26. Nolen B, Velikokhatnaya L, Marrangoni A, De GK, Lomakin A, et al. (2010) Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 117: 440-445.
27. Amonkar SD, Bertenshaw GP, Chen TH, Bergstrom KJ, Zhao J, et al. (2009) Development and preliminary evaluation of a multivariate index assay for ovarian cancer. PLoS One 4: e4599.
28. Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, et al. (2008) Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 110: 374-382.
29. Zheng Y, Katsaros D, Shan SJ, de la Longrais IR, Porpiglia M, et al. (2007) A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin Cancer Res 13: 6984-6992.
30. Yurkovetsky Z, Ta'asan S, Skates S, Rand A, Lomakin A, et al. (2007) Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol 107: 58-65.
31. Toriola AT, Grankvist K, Agborsangaya CB, Lukanova A, Lehtinen M, et al. (2011) Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: a longitudinal study. Ann Oncol 22: 1916-1921.
32. Lundin E, Dossus L, Clendenen T, Krogh V, Grankvist K, et al. (2009) C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy). Cancer Causes Control 20: 1151-1159.
33. Burger RA, Darcy KM, DiSaia PJ, Monk BJ, Grosen EA, et al. (2004) Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study. Cancer 101: 106-115.
34. Baron-Hay S, Boyle F, Ferrier A, Scott C (2004) Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res 10: 1796-1806.
35. Lu D, Kuhn E, Bristow RE, Giuntoli RL, Kjaer SK, et al. (2011) Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol 122: 560-566.
36. Edgell T, Martin-Roussety G, Barker G, Autelitano DJ, Allen D, et al. (2010) Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol 136: 1079-1088.
37. Kim K, Visintin I, Alvero AB, Mor G (2009) Development and validation of a protein-based signature for the detection of ovarian cancer. Clin Lab Med 29: 47-55.
38. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, et al. (2008) Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14: 1065-1072.
39. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, et al. (2005) Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 102: 7677-7682.
40. Yurkovetsky Z, Ta'asan S, Skates S, Rand A, Lomakin A, et al. (2007) Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol 107: 58-65.
41. Ben-Hamo R, Efroni S (2012) Biomarker robustness reveals the PDGF network as driving disease outcome in ovarian cancer patients in multiple studies. BMC Systems Biology 6: 3.
42. Robert A (2011) Overview of anti-angiogenic agents in development for ovarian cancer. Gynecologic Oncology 121: 230-238.
43. Rahbari N, Schmidt T, Falk C, Hinz U, Herber M, et al. (2011) Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer 11: 286.
44. Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A (2011) Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients. Int J Gynecol Cancer 21: 1040-1047.
45. Mury D, Woelber L, Jung S, Eulenburg C, Choschzick M, et al. (2011) Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer. J Cancer Res Clin Oncol 137: 1131-1137.
46. Tang A, Kondalsamy-Chennakesavan S, Ngan H, Zusterzeel P, Quinn M, et al. (2012) Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: A multinational collaborative study (ANZGOG0801). Gynecol Oncol.
47. Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, et al. (2011) Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. J Natl Cancer Inst 103: 1338-1342.
48. Skaznik-Wikiel ME, Sukumvanich P, Beriwal S, Zorn KK, Kelley JL, et al. (2011) Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report. Int J Gynecol Cancer 21: 1013-1017.
49. van Altena AM, Kolwijck E, Spanjer MJ, Hendriks JC, Massuger LF, et al. (2010) CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study. Gynecol Oncol 119: 265-269.
50. Zheng Y, Katsaros D, Shan SJ, de la Longrrais IR, Porpiglia M, et al. (2007) A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin Cancer Res 13: 6984-6992.
51. Baron-Hay S, Boyle F, Ferrier A, Scott C (2004) Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res 10: 1796-1806.